BCR-ABL constitutively activates tyrosine kinases (TK) that drives both Ph+ CML and Ph+ acute lymphoblastic leukemia (ALL) [3]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.